(NASDAQ: CORT) Corcept Therapeutics's forecast annual revenue growth rate of 37.76% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.46%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.88%.
Corcept Therapeutics's revenue in 2026 is $830,813,000.On average, 7 Wall Street analysts forecast CORT's revenue for 2026 to be $122,583,582,198, with the lowest CORT revenue forecast at $106,709,332,599, and the highest CORT revenue forecast at $131,447,650,752. On average, 7 Wall Street analysts forecast CORT's revenue for 2027 to be $184,307,766,885, with the lowest CORT revenue forecast at $148,527,197,478, and the highest CORT revenue forecast at $234,033,029,505.
In 2028, CORT is forecast to generate $232,519,651,947 in revenue, with the lowest revenue forecast at $185,929,242,840 and the highest revenue forecast at $322,889,911,839.